Sanofi's lixisenatide diabetes drug shows positive results
http://www.knowabouthealth.com/sanofis-lixisenatide-diabetes-drug-shows-positive-results/6547/

Sanofi 's lixisenatide diabetes drug shows positive results  Pharmaceutical companies are aggressively looking into development of drugs for patients suffering from type-2 diabetes mellitus . We read about Priamal , Indian pharma company , entering into phase-II trial with its P1736-05 compound . Sanofi reported results of phase -- III trial , GetGoal clinical trial program . The program was designed to assess the efficacy and safety of lixisenatide , a once-daily GLP-1 receptor agonist , as monotherapy in patients with type 2 diabetes .  About the studyLixisenatide , a glucagon-like peptide-1 agonist ( GLP-1 ) , is in development for the treatment of patients with type 2 diabetes mellitus . The study included :  Population of 361 patients with type 2 diabetes .  randomly receipt of either lixisenatide , the Sanofi 's diabetes injectable , or a placebo treatment .  is part of the new GLP-1 class of diabetes drugs . Other pharma giants are also working on this class of drugs , such as Byetta , marketed by Eli Lilly &amp; Co. and Amylin Pharmaceuticals Inc , and Novo Nordisk GLP-1 class drug like Novo Nordisk 's Victoza was approved with a warning about the risk for thyroid cancer and the requirement of a risk-mitigation strategy .